Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
Read original at benzingaStocks · News reference
Dyne Therapeutics' Biologics License Application For Zeleciment Rostudirsen Got FDA Acceptance For Review To Treat Duchenne Muscular Dystrophy
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the U.S. Food and Drug
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 11:32 AM
- Checked
- Jul 20, 2026, 11:32 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35
Read original at benzingaDyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
Read original at benzinga8-K filing — Dyne Therapeutics, Inc. (DYN)
Filed: 2026-07-29 AccNo: 0001193125-26-323940 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar